Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ancient herbal formula put to the test for boosting egg maturity

NCT ID NCT07737847

Knowledge-focused Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This study tests whether ShouTai Pills, a traditional Chinese herbal remedy, can improve egg quality in women with diminished ovarian reserve (DOR) who are undergoing IVF. Researchers will analyze follicular fluid to identify biological markers that predict who might benefit. The goal is to see if the pills increase the number of mature eggs retrieved and improve hormone levels.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ShouTai Pills, a traditional Chinese herbal medicine
What this could lead to
If the pills improve egg maturity and hormone levels, this could point toward a new treatment option for women with diminished ovarian reserve.
What could go wrong
This is an early-stage study with a small sample size. The placebo effect is possible, and the herbal formula's mechanism is not well understood.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 136 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 50 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. The inclusion criteria are as follows: ① meeting the above-mentioned integrated Chinese and Western medicine diagnostic criteria for DOR 2. ② no use of estrogen-containing medications within the past 1 month 3. ③ patients scheduled to undergo IVF-ET 4. ④ provision of signed informed consent, voluntary participation, and good compliance. Exclusion Criteria: 1. The exclusion criteria are as follows: ① patients with polycystic ovary syndrome (PCOS) or stage III/IV endometriosis 2. ② uterine conditions including untreated submucous myomas, intramural myomas \>4 cm in diameter, intrauterine adhesions, uterine septum, or other uterine anomalies 3. ③ couples undergoing preimplantation genetic diagnosis (PGD) for genetic reasons 4. ④ body mass index (BMI) ≥28 kg/m² 5. ⑤ history of prior pelvic radiotherapy or cytotoxic chemotherapy 6. ⑥ significant systemic diseases, such as uncontrolled hypertension, diabetes mellitus, thyroid dysfunction, hepatic or renal insufficiency, cardiac disorders, or autoimmune diseases 7. ⑦ use of medications that may interfere with this study within the past 1 month, including but not limited to estrogens, hepatic enzyme modulators, and agents that may affect the endocrine system (hormonal drugs) 8. ⑧ known allergy to any components of the study medication 9. and ⑨ participation in another drug trial within the past 3 months. -

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diminished ovarian reserve are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ovarian dysfunction primary ovarian failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diminished ovarian reserve (DOR)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, 100732, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.